Lehane D E, Watson S, Lane M
Cancer. 1975 May;35(5):1421-5. doi: 10.1002/1097-0142(197505)35:5<1421::aid-cncr2820350527>3.0.co;2-s.
The nitroblue tetrazolium test (NBT) was evaluated in 111 patients with cancer. Patients were placed into control and "presumed infected" groups. The mean NBT score for the control group, 6.3, was significantly greater than the mean for a group of normal volunteers, 3.1, but the mean score for the "presumed infected" group, 15.6 was significantly higher. Less than 10 percent of the patients with bacterial infection had scores below 10, while 15 percent of the control patients had unexplained high scores. A method for concentrating leukocytes is described which makes the NBT test feasible in patients with granulocytopenia. Morphological changes in granulocytes used as indicators of infection are unreliable markers in cancer patients, in whom such changes occur frequently in the absence of infection. We have found that the NBT test is more useful as an indicator of infection in patients with cancer.
对111例癌症患者进行了硝基蓝四氮唑试验（NBT）。患者被分为对照组和“疑似感染”组。对照组的平均NBT评分为6.3，显著高于一组正常志愿者的平均分3.1，但“疑似感染”组的平均评分为15.6，显著更高。细菌感染患者中不到10%的患者评分低于10，而对照组中有15%的患者有无法解释的高分。描述了一种浓缩白细胞的方法，该方法使NBT试验在粒细胞减少症患者中可行。用作感染指标的粒细胞形态变化在癌症患者中是不可靠的标志物，在这些患者中，此类变化在无感染时也经常发生。我们发现，NBT试验作为癌症患者感染的指标更有用。
